



## **MEDIA RELEASE**

### **SAHPRA Statement on the ANHP Judgement**

**Embargo: Immediate release**

**Pretoria, 07 May 2022** - Following the ruling by the Supreme Court of Appeal (SCA) in favour of the Alliance of Natural Health Products in South Africa (ANHP) on 11 April 2022, the South African Health Products Regulatory Authority (SAHPRA) will join the Minister of Health in approaching the Constitutional Court for leave to appeal the judgement.

Issued by:

Dr Boitumelo Semete

**CEO**

**Boitumelo.semete@sahpra.org.za**

**For further enquiries /information contact:**

**Media contact:**

Ms Nthabi Moloi

Cell: 082 407 8854

**E-mail: [Nthabi.moloi@sahpra.org.za](mailto:Nthabi.moloi@sahpra.org.za)**

## **Notes**

1. The Supreme Court of Appeal judgment in Minister of Health and Another v Alliance of Natural Health Products (South Africa) (Case no 256/2021) [2022] ZASCA 49 (11 April 2022) is accessible at: <https://www.supremecourtofappeal.org.za/index.php/component/jdownloads/summary/38-judgments-2022/3781-minister-of-health-and-another-v-alliance-of-natural-health-products-south-africa-case-no-256-2021-2022-zasca-49-11-april-2022>

**About SAHPRA:**

SAHPRA is tasked with regulating (by the monitoring, evaluation, regulation, investigation, inspection, registration, and control of) medicines, scheduled substances, clinical trials, and medical devices, IVDs and related matters in the public interest. Furthermore, SAHPRA has the added responsibility of overseeing radiation control in South Africa. SAHPRA's mandate is outlined in the Medicines and Related Substances Act, 1965 (Act No 101 of 1965) as well as the Hazardous Substances Act, 1973 (Act No 15 of 1973).

SAHPRA has three pillars to ensure that medicines, medical devices and IVDs meet the requisite standards to protect the health and well-being of all who reside in South Africa:

- Safety
- Efficacy
- Quality

It is these three pillars that define the ethos of SAHPRA.